Kirkland & Ellis is advising KKR on the financing for its investment in Immedica Pharma, a Swedish pharmaceutical company focused on medicines for rare diseases and specialty care. Immedica Pharma’s existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
The debt facilities will, among other things, be used for acquisition proceeds as well as the ongoing capital expenditure and working capital requirements of the group.
The Kirkland team consisted of debt finance partners Ian Barratt and Jia Meng, with the support of debt finance associates Deena Smith and Ashley Bannister.
